If your insurance has declined to cover a GLP-1 because your plan excludes weight-loss drugs, there is a question worth asking that most patients never do: am I being assessed for the right indication?
The FDA has granted these medications approvals that have nothing to do with weight loss as such. Zepbound was approved in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity — the first medication ever approved for OSA. And Wegovy is approved for lowering cardiovascular risk in overweight or obese individuals, for secondary prevention of cardiovascular events.
Analysis of the approvals notes that to date the FDA has granted two non-obesity indications across these products: OSA for Zepbound, and secondary prevention of cardiovascular events for Wegovy.
This matters practically rather than academically. Plans that exclude weight-loss drugs frequently cover medications prescribed for a different, covered condition. If you have obstructive sleep apnea or established cardiovascular disease, your route to coverage may run through that diagnosis rather than your BMI.
The Approved Non-Obesity Indications
Zepbound for Obstructive Sleep Apnea
The FDA approved Zepbound in December 2024 for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity — the first medication ever approved for OSA. Reporting notes a BMI threshold of 30 or higher applies.
Wegovy for Cardiovascular Risk Reduction
The FDA approved Wegovy for lowering cardiovascular risk in overweight or obese individuals. Analysis describes this as secondary prevention of cardiovascular events — that is, in people who already have established cardiovascular disease.
Wegovy Also Has a Liver Indication
Coverage comparing the two products notes Wegovy is additionally approved to treat a type of fatty liver disease, which is a further non-obesity route worth raising if it applies to you.
These Are Different Drugs With Different Approvals
Zepbound has the sleep apnea indication; Wegovy has the cardiovascular one. They are not interchangeable for coverage purposes, which means the right medication may depend on your diagnosis rather than your preference.
It Can Change Your Coverage Position
Plans that exclude weight-loss drugs often cover medication prescribed for a covered condition. If you have OSA or established cardiovascular disease, that is a different conversation with your insurer than a BMI-based one.
Zepbound and Obstructive Sleep Apnea
This approval was genuinely historic. Obstructive sleep apnea has been managed for decades primarily with CPAP and, in some cases, surgery. There had never been an approved medication for it until the FDA approved Zepbound in December 2024 for moderate-to-severe OSA in adults with obesity.
The mechanism is straightforward: the FDA notes that by reducing body weight, studies show Zepbound also improves OSA. Excess weight contributes to airway obstruction during sleep, and reducing it reduces the obstruction. Published work has explored tirzepatide’s effects on OSA specifically alongside its glycaemic, weight and cardiovascular effects.
For a patient with both obesity and moderate-to-severe OSA, this changes the framing entirely. You are not asking your insurer to cover a weight-loss drug. You are asking it to cover the only approved medication for a condition you have been diagnosed with.
You Need a Diagnosis
This route requires a documented OSA diagnosis, typically via a sleep study. If you have symptoms — loud snoring, witnessed apnoeas, daytime sleepiness — but no diagnosis, that assessment is the first step and it is worth pursuing on its own merits.
It Is Zepbound Specifically
The OSA indication belongs to Zepbound (tirzepatide). Reporting has noted the question of why Zepbound and not Wegovy carries it — the answer is which company ran which trials. For coverage purposes, the distinction is what matters.
Coverage Is Still Not Guaranteed
An approved indication improves your position; it does not guarantee approval. Plans may still apply prior authorisation or step therapy. But arguing from a covered diagnosis is a considerably stronger starting point than arguing from BMI alone.
Wegovy and Cardiovascular Risk
The FDA approved Wegovy for lowering cardiovascular risk in overweight or obese individuals. Analysis of the approvals characterises this as secondary prevention of cardiovascular events — meaning it applies to people with established cardiovascular disease rather than as primary prevention in otherwise healthy people.
That distinction matters for who qualifies. If you have had a cardiovascular event or carry a diagnosis of established cardiovascular disease alongside overweight or obesity, this indication may apply to you. If your cardiovascular risk is elevated but you have no established disease, it likely does not.
Coverage comparing Wegovy and Zepbound also notes Wegovy is approved to treat a type of fatty liver disease, giving it a second non-obesity route.
As with the OSA pathway, the practical value is in reframing the coverage conversation. A prescription written against a cardiovascular indication is a different proposition to a plan than one written against obesity.
How to Use This With Your Insurer
This is not a loophole and it should not be approached as one. It is about ensuring your prescription reflects your actual clinical picture.
1. Establish Whether You Have a Qualifying Diagnosis
Do you have diagnosed moderate-to-severe obstructive sleep apnea? Established cardiovascular disease? A diagnosed fatty liver condition? These are clinical facts, not framing choices — and if you have them, they are relevant.
2. Raise It With Your Prescriber Explicitly
Your clinician decides what to prescribe and for what indication. Bring the question rather than assuming it has been considered — many weight-management consultations never touch on OSA or cardiovascular history in this context.
3. Match the Molecule to the Indication
Zepbound carries the OSA indication; Wegovy carries the cardiovascular one. If your route to coverage runs through a specific diagnosis, the appropriate medication may be determined by that rather than by preference.
4. Expect Prior Authorisation Anyway
A covered indication strengthens your case but rarely removes the process. Our guidance on step therapy and prior authorisation applies here too — and providers like Measured build their service around handling it.
5. Check the Medicare Position Separately
If you are on Medicare, the GLP-1 Bridge is a distinct pathway with its own rules and a $50 copay. Diagnosis-based coverage under Part D and the Bridge are different routes — check both.
Our Take
If your plan has declined a GLP-1 as a weight-loss drug, the indication question is worth raising before you accept that answer. The FDA has granted two non-obesity indications across these products — obstructive sleep apnea for Zepbound and secondary cardiovascular prevention for Wegovy — and plans that exclude weight-loss drugs frequently cover medication for a diagnosed condition.
The sleep apnea approval deserves more attention than it gets. Zepbound is the first medication ever approved for OSA. For a patient managing both obesity and moderate-to-severe sleep apnea, that is not a coverage technicality — it is a treatment option that did not exist before December 2024, addressing a condition with real consequences for cardiovascular health and daily functioning.
Be honest about whether the indication applies. This works when your clinical picture genuinely includes a qualifying diagnosis. It is not a script to recite — it is a prompt to make sure your prescriber has the full picture, because weight-management consultations frequently do not cover sleep or cardiovascular history in any depth.
And if you have symptoms but no diagnosis, pursue the assessment on its own merits. Undiagnosed obstructive sleep apnea is worth identifying whether or not it changes your GLP-1 access. If it does both, better still. For the coverage process itself, Measured and our insurance guide are the practical next steps.
Frequently Asked Questions
Is Zepbound approved for sleep apnea?
Yes. The FDA approved Zepbound in December 2024 for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. It was the first medication ever approved for OSA. Reporting notes a BMI threshold of 30 or higher applies to the indication.
Why is Zepbound approved for OSA but not Wegovy?
The indications reflect which company conducted which clinical trials. Analysis of the approvals notes the FDA has granted two non-obesity indications across these products: OSA for Zepbound and secondary prevention of cardiovascular events for Wegovy. For coverage purposes, the distinction is what matters.
Is Wegovy approved for heart disease?
Wegovy is approved for lowering cardiovascular risk in overweight or obese individuals. Analysis characterises this as secondary prevention of cardiovascular events, meaning it applies to people with established cardiovascular disease rather than as primary prevention in otherwise healthy people.
Will an OSA diagnosis get my GLP-1 covered?
It can substantially strengthen your position, because plans that exclude weight-loss drugs frequently cover medication prescribed for a diagnosed condition. It does not guarantee approval — prior authorisation and step therapy may still apply. But arguing from a covered diagnosis is a stronger starting point than arguing from BMI alone.
How does Zepbound help sleep apnea?
The FDA notes that by reducing body weight, studies show Zepbound also improves OSA. Excess weight contributes to airway obstruction during sleep, so reducing it reduces obstruction. Published work has examined tirzepatide’s effects on OSA alongside its glycaemic, weight and cardiovascular effects.
Do I need a sleep study?
A documented diagnosis of moderate-to-severe obstructive sleep apnea is what the indication rests on, and that typically requires a sleep study. If you have symptoms such as loud snoring, witnessed pauses in breathing or significant daytime sleepiness, that assessment is worth pursuing on its own merits regardless of GLP-1 access.
Are there other non-weight indications?
Coverage comparing the two products notes Wegovy is also approved to treat a type of fatty liver disease. Beyond that, analysis indicates the FDA has to date granted two non-obesity indications across Zepbound and Wegovy — OSA and secondary cardiovascular prevention respectively. Other uses are being researched but are not approved.
Does this apply to compounded GLP-1s?
No. Approved indications belong to approved products. Compounded preparations are not FDA-approved and carry no indications, so they cannot be prescribed against an approved OSA or cardiovascular indication and are not covered by insurance on that basis.
Disclosure:
This article is based on publicly available information including FDA press announcements regarding the approval of the first medication for obstructive sleep apnea, FDA labelling and approval information for Zepbound and Wegovy, published research on tirzepatide and obstructive sleep apnea indexed in PubMed Central, and clinical and trade analysis of non-obesity indications for these products, current as of August 2026. Presidential GLP-1 may receive compensation from some providers featured on this site, which helps us provide free, independent reviews. Approved indications and coverage criteria may change, and coverage decisions rest with your individual plan — verify directly. Nothing here is medical advice: whether a particular indication applies to you is a clinical determination for a clinician who knows your history, not a framing choice. We do not sell, dispense, or ship medication.
⚕ Medical Disclaimer:
This article is for informational purposes only and is not medical advice. Prescription weight-management medications carry serious risks and contraindications; GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors. Only a licensed clinician who knows your medical history can determine whether any weight-management medication is appropriate for you. See our full medical disclaimer.
Related Guides & Articles
LifeMD
Brand-name Wegovy and Zepbound prescribing with insurance assistance and lab work included.
GLP-1 Insurance, HSA and FSA Guide
Coverage, appeals and pre-tax payment in full.
The Medicare GLP-1 Bridge
A separate pathway offering a $50 copay for eligible Part D beneficiaries.
GLP-1 Eligibility
Who qualifies clinically, and how criteria differ from insurance criteria.
Mounjaro / Zepbound Review
The tirzepatide products, including the OSA indication.
Compare All GLP-1 Providers
Read our independent reviews of every provider we cover
View All Reviews →